ckd complications
Anaemia (KDIGO 2026): screen with CBC, retics, ferritin and TSAT. Iron first, with new non-dialysis thresholds (ferritin <100 + TSAT <40%, or ferritin 100–300 + TSAT <25%). ESA over HIF-PHI; Hb target <115 g/L. MBD: lower phosphate towards normal, limit calcium binders, avoid hypercalcaemia, no routine calcitriol before G4–5. Acidosis: treat to prevent HCO₃⁻ <18 (KDIGO 2024). K⁺ → potassium disorders. Plan KRT or conservative care from 2-year KFRE >40% or eGFR <15–20.
anaemia — KDIGO 2026
screening and work-up
| CKD stage | Hb at least |
|---|---|
| G3 | yearly |
| G4 | twice a year |
| G5/G5D | every 3 months |
- Anaemia = Hb <130 g/L (male), <120 g/L (female). First panel: CBC, reticulocytes, ferritin, TSAT
- Ferritin <45 µg/L or MCV <80 → look for blood loss (GI, gynae, urology)
- Unexplained → smear, haemolysis screen, CRP, B12/folate, LFTs, SPEP/FLC/urine BJP, TSH, PTH, FOBT
- Correct reversible causes (iron, B12/folate, infection, hyperparathyroidism, inadequate dialysis, hypothyroidism, haemolysis) before an ESA
iron, ESA and HIF-PHI — doses and titration → ESAs and IV iron
- Iron first. Non-dialysis/PD: start if ferritin <100 + TSAT <40%, or ferritin 100–300 + TSAT <25% (oral or IV). Haemodialysis: ferritin ≤500 + TSAT ≤30%, IV proactive. Withhold if ferritin >700 or TSAT ≥40%
- Then ESA if Hb stays low and symptoms or transfusion avoidance justify it — shared decision against stroke, CV events and cancer. Dialysis: start at Hb ≤90–100 g/L; non-dialysis/transplant: individualise
- Target Hb <115 g/L (1D). ESA over HIF-PHI first line (2D)
- Hyporesponsive → rework the reversible causes above before escalating
- Transfusion on symptoms, not a number; avoid in transplant candidates (allosensitisation)
- General iron-deficiency work-up and formulations → iron deficiency
Non-dialysis iron thresholds moved from “ferritin ≤500 and TSAT ≤30%” to ferritin <100 with TSAT <40%, or ferritin 100–300 with TSAT <25%. The ≤500/≤30% rule now applies to haemodialysis only. The Hb ceiling of 115 g/L is unchanged. CSN 2015 (older) advised screening for anaemia only once eGFR <30.
CKD–mineral and bone disorder — KDIGO 2017
monitoring (from G3a)
| stage | Ca, PO₄ | PTH | ALP |
|---|---|---|---|
| G3a–3b | 6–12 monthly | by baseline and progression | — |
| G4 | 3–6 monthly | 6–12 monthly | yearly |
| G5/G5D | 1–3 monthly | 3–6 monthly | yearly |
- 25(OH)D may be measured; correct deficiency as for the general population
- Act on trends, not single values. Use Ca and PO₄ separately; Ca × P product isn’t recommended
- Known vascular or valvular calcification = highest CV risk. Lateral abdominal X-ray or echo are acceptable screens
phosphate and calcium
- Lower phosphate towards the normal range when it is persistently or progressively high (2C). Treating early or to normal isn’t the goal
- Avoid hypercalcaemia (2C); restrict calcium-based binders (2B); never long-term aluminium (1C) → phosphate binders
- Limit dietary phosphate, especially additives in processed food (2D). Dialysis → increase dialytic removal
- Dialysate Ca 1.25–1.50 mmol/L
PTH
- Non-dialysis: optimal PTH unknown. Rising or above normal → look for high phosphate, low calcium, high phosphate intake, vitamin D deficiency (2C)
- No routine calcitriol or analogues in G3a–G5 (2C). Reserve for G4–5 with severe, progressive hyperparathyroidism
- Dialysis: iPTH ≈2–9× the upper limit of normal (2C); marked changes in either direction within the range → start or change therapy (2C). Lower PTH with calcimimetic (cinacalcet), calcitriol or analogue, or a combination (2B)
- Refractory severe hyperparathyroidism → parathyroidectomy (2B)
bone
- G1–2, or G3 with normal PTH: treat osteoporosis as for the general population
- G3a–G5D with MBD lab abnormalities + low BMD or fracture → individualise; consider bone biopsy before antiresorptives
- BMD testing if it changes management (2B)
metabolic acidosis — KDIGO 2024
- Treat (drug ± diet) to prevent HCO₃⁻ <18 mmol/L in adults
- Don’t overshoot the upper normal limit; watch BP, K⁺ and volume (sodium load) → sodium bicarbonate
- The old KDIGO 2012 aim of “keep HCO₃⁻ ≥22” was replaced by this lower, practice-point threshold
other complications
hyperkalaemia
- Measurement varies (serum vs plasma, time of day, haemolysis)
- G3–G5 with prior hyperkalaemia → limit foods rich in bioavailable K⁺ (processed foods), renal dietitian
- Keep RASi/MRA going with diuretics or binders; action bands by K⁺ level (UKKA, Diabetes Canada) → potassium disorders, potassium binders
gout and urate — KDIGO 2024
- Symptomatic hyperuricaemia → urate lowering (1C); consider after the first gout attack (especially urate >535 µmol/L). Xanthine oxidase inhibitor over uricosurics
- Acute flare: low-dose colchicine or steroid (intra-articular or oral) over NSAIDs
- Asymptomatic hyperuricaemia: don’t treat to slow CKD (2D)
cardiovascular and AF
- Statin, aspirin and AF → chronic kidney disease
- DOACs over warfarin in G1–G4; dose by GFR → DOAC dosing in renal impairment and obesity
uraemic symptoms, nutrition, KRT planning
- Ask about appetite, nausea, fatigue and pruritus at each visit (validated tool)
- Screen for malnutrition twice a year if G4–5, age >65, weight loss or frailty
- Plan pre-emptive transplant and/or dialysis access when eGFR <15–20 or 2-year KFRE >40%
- Start dialysis on a composite of symptoms and signs, not eGFR alone. Usually eGFR 5–10 when one of these is present:
- uraemic serositis, encephalopathy or pruritus
- refractory acid–base/K⁺ problems
- uncontrollable volume or BP
- declining nutrition or cognition
- Urgent dialysis (AEIOU: acidosis, electrolytes, ingestions, overload, uraemia) → dialysis overview
- Conservative kidney management (no KRT) is a legitimate choice. Offer it alongside KRT, with advance care planning
Prepared 2026-11-01. Not yet verified — check every number against the sources.